Pharmaceutical start-up AcadeMab Biomedical Inc (研生生醫) said it has been developing a COVID-19 antibody drug, an endeavor not being undertaken by many other Taiwanese pharmaceutical firms.
The company was spun off from Academia Sinica’s Institute of Cellular and Organismic Biology in 2020 and has only 16 employees. It has set its sights on the innovative field of the monoclonal antibody treatment of tumors.
The start-up began developing antibody drugs in January, after seeing that COVID-19 vaccines could not effectively protect people from new variants of SARS-CoV-2, AcadeMab Biomedical chief strategy officer Pearl Fong (俸清珠) said in an interview with the Taipei Times on Thursday.
Photo courtesy of AcadeMab Biomedical Inc
The development of COVID-19 antibody drugs focuses on the sequences of the antibodies produced in the body following vaccination, Fong said.
The method does not require any information on the sequences of SARS-CoV-2, she said.
“Specifically, we need to know the DNA sequences of the Y-shaped antibodies carried by people’s memory B cells. Once we obtain the sequences, we can replicate the antibodies,” she added.
The start-up for at least four weeks collected blood samples from five people who had received three doses of COVID-19 vaccines. It then used a method called “cell shorting” to isolate memory B cells and used genetic engineering to decode the sequences of the antibody, AcadeMab Biomedical project manager Chiang Pao-yin (姜伯穎) said.
Getting the right sequences was not easy, Chiang said.
A 20 to 30 milliliter blood sample contains about 40 million cells, from which about 100,000 memory B cells can be isolated, Chiang said.
Using advanced technology, the company initially obtained about 2,000 sequences of antibodies and selected 163 that were expected to be the most effective in fighting against SARS-CoV-2 variants, he said.
“It is like making a key. It must not only have the right shape to fit in the hole, but it also has to be long enough to be used. The right antibodies must not only bind with the spike protein of the virus, but bind firmly,” Chiang said.
The start-up selected 10 sequences and tested them against the Omicron subvariants of SARS-CoV-2 and eventually chose four that showed the most potential, Chiang said, adding that its experimental drug is called SB-001.
Explaining how antibody drugs fight against new SARS-CoV-2 variants while vaccines cannot, Fong said that vaccines and antibody drugs use different mechanisms.
Vaccines prompt the immune system to produce antibodies, but after a given period, only a few antibodies that are most effective against a variant remain in the body, Fong said.
However, it is possible that these antibodies cannot attack new subvariants, she said.
Developers of COVID-19 antibody drugs have deep knowledge of antibody sequences, Fong said.
“It’s like we have a database. We can always research which sequence works best against the latest subvariant and change our formula accordingly,” Fong said.
An antibody that does not work well against an older subvariant could be effective against a new subvariant, she added.
“That has been the case with Eli Lilly and Co. Its first two antibody drugs were approved, but they did not work against later Omicron subvariants. However, the company found another sequence and used it to develop a new antibody drug,” Fong said.
AcadeMab Biomedical is one of only a few Taiwanese companies working on COVID-19 antibody drugs, she said.
Fong said there are two reasons that Taiwanese companies prefer to develop COVID-19 vaccines over antibody drugs, with about 10 firms working on vaccines.
“First, vaccines use fewer proteins than antibody drugs, so vaccine developers can conduct research more easily with limited manufacturing capacity. Second, the requirements for clinical trials involving antibody drugs are much stricter than those for vaccines,” she said.
Antibody drugs are mainly used for treatment instead of prevention, Fong said, adding that they can be used for prevention in some cases, she said.
People who are planning to travel to high-risk areas could take the drugs before embarking on their trip, she said.
As AcadeMab Biomedical focuses on research, it plans to find a manufacturing partner to codevelop SB-001, Fong said, adding that the company has been in talks with several firms and hopes to finalize a deal by the end of this year.
It plans to apply for emergency use authorization in the US and hopes to start phase 1 human trials by June next year, she said.
US-based tech giant Google said yesterday that its efforts to build four underseas cables to connect Taiwan with the world had created more than 64,000 jobs and generated about US$26 billion in GDP for Taiwan as of 2021. The US company has transformed Taiwan into a strategic cloud infrastructure hub in the world. The four undersea cables are part of the company’s investments in cloud infrastructure in Taiwan, and on the back of the undersea cables, a data center and a Google Cloud Region, which is a geographic area in which Google provides infrastructure and services for deploying applications, Google said in
Huawei Technologies Co (華為) largely omitted mention of its controversial Mate 60 smartphone series at a grand showcase of its new consumer products yesterday. The Shenzhen-based company would increase smartphone production in response to demand, said consumer division chief Richard Yu (余承東), without naming the handset triggering that surge. The Mate 60 Pro earned international notoriety with its advanced made-in-China processor last month, causing concern in Washington about Huawei’s progress toward developing in-house chipmaking capabilities despite US trade curbs. Huawei’s new phones have fired up the company’s sales and were among the top sellers in China in the week before Apple Inc’s
SLUMP: The electronics, machinery and traditional industries posted the largest decline in the past year; overall, sectors showed gains over the previous month Taiwan’s industrial production index decreased 10.53 percent year-on-year to 91.38 last month, falling for a 15th consecutive month on an annual basis, as weak global economic growth continued to weigh on end-market demand and investment momentum, the Ministry of Economic Affairs said on Saturday. The industrial production index gauges output in Taiwan’s four main industries: manufacturing, electricity and gas supply, water supply, and mining and quarrying. Last month’s decline was the smallest contraction since March when the index dropped 16.03 percent from a year earlier. On a monthly basis, the index rose 7.28 percent, marking a second straight month of improvement,
Micron Technology Inc on Wednesday predicted a steeper loss than anticipated in the current quarter, indicating that an industry slump is still weighing on the largest US maker of memory chips. The company projected a fiscal first-quarter loss of as much as US$1.14 a share, excluding some items. Analysts had estimated a US$0.96 loss. On the bright side, revenue is expected to start recovering in the period. Micron predicted sales of US$4.2 billion to US$4.6 billion, compared with an estimate of US$4.21 billion. For Micron and competitors Samsung Electronics Co and SK Hynix Inc, this year has been brutal. Customers in their